MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Ankit P., Patel, Krishna, Pinto, Sneha, Radhakrishnan, Aneesha, Nanjappa, Vishalakshi, Kumar, Manish, Raja, Remya, Patil, Arun H., Kumari, Anjali, Manoharan, Malini, Karunakaran, Coral, Murugan, Saktivel, Keshava Prasad, T. S., Chang, Xiaofei, Mathur, Premendu Prakash, Kumar, Prashant, Gupta, Ravi, Gupta, Rohit, Khanna-Gupta, Arati, Sidransky, David, Chatterjee, Aditi, Gowda, Harsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://www.ncbi.nlm.nih.gov/pubmed/31827134
http://dx.doi.org/10.1038/s41598-019-55208-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://www.ncbi.nlm.nih.gov/pubmed/31827134
http://dx.doi.org/10.1038/s41598-019-55208-5

Ejemplares similares